Primary mucoepidermoid carcinoma of the trachea in a child
Department of Cardiothoracic Surgery, Edith Wolfson Medical Center, Holon, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Interactive Cardiovascular and Thoracic Surgery
(Impact Factor: 1.16).
05/2012; 15(2):311-2. DOI: 10.1093/icvts/ivs199
Mucoepidermoid carcinoma of the trachea is a rare tumour, especially in the paediatric population. We report the case of a
9-year-old boy with mucoepidermoid carcinoma of the trachea that was preoperatively diagnosed as an intraluminal polypoid
mass arising from the trachea and extending into the right main bronchus. A complete resection of the tumour with reconstruction
and end-to-end anastomosis of the trachea was performed. The patient is now, 24 months after surgery, free of disease.
Available from: Mei Ling Lim
- "This is particularly true in the paediatric population. The most common tracheal neoplasm reported in children is mucoepidermoid carcinoma, a salivary gland-type cancer , . The mucoepidermoid tumors are histologically heterogenous low-grade tumors that grow locally, without metastasis , , . "
[Show abstract] [Hide abstract]
ABSTRACT: Stem cells contribute to regeneration of tissues and organs. Cells with stem cell-like properties have been identified in tumors from a variety of origins, but to our knowledge there are yet no reports on tumor-related stem cells in the human upper respiratory tract. In the present study, we show that a tracheal mucoepidermoid tumor biopsy obtained from a 6 year-old patient contained a subpopulation of cells with morphology, clonogenicity and surface markers that overlapped with bone marrow mesenchymal stromal cells (BM-MSCs). These cells, designated as MEi (mesenchymal stem cell-like mucoepidermoid tumor) cells, could be differentiated towards mesenchymal lineages both with and without induction, and formed spheroids in vitro. The MEi cells shared several multipotent characteristics with BM-MSCs. However, they displayed differences to BM-MSCs in growth kinectics and gene expression profiles relating to cancer pathways and tube development. Despite this, the MEi cells did not possess in vivo tumor-initiating capacity, as proven by the absence of growth in situ after localized injection in immunocompromised mice. Our results provide an initial characterization of benign tracheal cancer-derived niche cells. We believe that this report could be of importance to further understand tracheal cancer initiation and progression as well as therapeutic development.
Available from: Ugo Cioffi
- "We read with interest the paper by Papiashvilli and co-authors, reporting on an interesting case of mucoepidermoid carcinoma of the lower trachea in a 9-year old boy . Mucoepidermoid carcinomas are rare neoplasms  of the bronchial tree arising from mucous and serous glands of the epithelium. "
[Show abstract] [Hide abstract]
ABSTRACT: Tracheal disease can be divided into tumors (benign and malignant) and manifestations of systemic processes. Primary malignant tumors of the trachea are rare, accounting for only 0.2% of all respiratory tract tumors, but must be distinguished from benign tumors by biopsy where possible. Bronchoscopy offers both diagnostic and therapeutic options for tracheal tumors, including various biopsy techniques, approaches that involve resection with rigid bronchoscopy, stenting, and laser ablation. Systemic diseases frequently have tracheal manifestations that can result in respiratory symptoms leading clinicians to perform bronchoscopy; a high clinical suspicion must be combined with knowledge of the tracheal manifestations and yield of bronchoscopic biopsy to successfully diagnose and treat these patients. We have examined the literature to enumerate the relevant tracheal tumors and conditions, and review the data supporting bronchoscopy use in these diseases.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.